tiprankstipranks
Trending News
More News >
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX

Royalty Pharma (RPRX) AI Stock Analysis

Compare
1,262 Followers

Top Page

RP

Royalty Pharma

(NASDAQ:RPRX)

Rating:78Outperform
Price Target:
$40.00
▲(9.98%Upside)
Royalty Pharma's strong financial performance, bolstered by impressive earnings call outcomes and solid technical indicators, supports a positive stock outlook. While valuation remains reasonable, ongoing regulatory disputes and potential overbought conditions slightly temper the overall bullish sentiment.
Positive Factors
Financial Strategy
The transaction sets Royalty Pharma on track to meet or exceed its 5-year capital deployment target, demonstrating confidence in their strategic direction.
Regulatory Approvals
FDA has granted Breakthrough Therapy Designation to daraxonrasib for previously treated metastatic PDAC in patients with KRAS G12 mutations.
Royalty Financing Deal
The announced royalty financing deal with Revolution Medicines allows Royalty Pharma to participate in the upside of the target asset daraxonrasib for oncology.
Negative Factors
Management Strategy
The move to internalize the manager simplifies financial reporting and provides clear alignment between management and shareholders, but it might disrupt current operations.
Market Competition
Tremfya should fight Skyrizi to a draw in ulcerative colitis, and RPRX garners a tiered mid-single digit royalty on Tremfya through 2031-32.
Pipeline Challenges
The company's growth profile is above the peer average, yet the lack of an internal pipeline could pose challenges to adapting to potential changes in the regulatory environment.

Royalty Pharma (RPRX) vs. SPDR S&P 500 ETF (SPY)

Royalty Pharma Business Overview & Revenue Model

Company DescriptionRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
How the Company Makes MoneyRoyalty Pharma makes money by acquiring royalty interests in drugs and biopharmaceutical products from various stakeholders, including academic institutions, research hospitals, and pharmaceutical companies. The company's primary revenue stream comes from the royalties it receives from the sales of these drugs, which can include treatments for a wide range of medical conditions. Royalty Pharma strategically invests in high-potential drugs and typically pays the original innovators a lump sum in exchange for a portion of future sales revenue. This model allows Royalty Pharma to benefit from the commercial success of these drugs. Additionally, the company often forms partnerships and collaborations to enhance its portfolio and maximize its revenue potential. Key factors contributing to its earnings include the success of the drugs in its portfolio, market expansion, and strategic acquisitions of new royalty interests.

Royalty Pharma Key Performance Indicators (KPIs)

Any
Any
Portfolio Receipts
Portfolio Receipts
Tracks the income generated from the company's portfolio of royalty interests, highlighting cash flow stability and the effectiveness of its investment strategy in acquiring lucrative royalty streams.
Chart InsightsRoyalty Pharma's Portfolio Receipts have shown significant growth, particularly in early 2023, reflecting a robust and diversified portfolio. The recent earnings call highlighted a 17% increase in Portfolio Receipts, driven by strong performance and strategic capital allocation, including a $2 billion share buyback plan. The company raised its full-year guidance, anticipating 6% to 12% growth, supported by promising developments like the Phase 3 R&D collaboration with Biogen. However, potential regulatory challenges and a royalty dispute with Vertex could pose risks to future growth.
Data provided by:Main Street Data

Royalty Pharma Earnings Call Summary

Earnings Call Date:May 08, 2025
(Q1-2025)
|
% Change Since: 11.80%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Positive
The earnings call highlighted Royalty Pharma's strong financial performance, dynamic capital allocation strategy, and significant portfolio expansions, alongside some concerns about policy uncertainties and ongoing disputes. The company remains optimistic about its future growth and market opportunities.
Q1-2025 Updates
Positive Updates
Strong Financial Performance
Royalty Receipts grew by 12% in the first quarter, reflecting the strength of the diversified portfolio. Portfolio Receipts, including milestone payments, grew by 17% to $839 million.
Dynamic Capital Allocation
Royalty Pharma repurchased $723 million of shares in the first quarter and announced a plan to repurchase up to $2 billion of shares in 2025, while also deploying over $100 million on value-creating royalty transactions.
Portfolio Expansion
Expansion of the development stage pipeline with a Phase 3 R&D funding collaboration with Biogen for litifilimab in lupus, and advancement of trontinemab into Phase 3 in Alzheimer’s disease.
Raised 2025 Financial Guidance
Increased full-year guidance for Portfolio Receipts to $2.975 billion to $3.125 billion, driven by the diversified portfolio's strength and a tailwind from weakening U.S. dollars.
Positive Phase 3 Results for Ecopipam
Reported positive Phase 3 results for ecopipam in Tourette’s syndrome, showing significant benefit and safety, with plans for FDA submission.
Negative Updates
Challenges with Regulatory Environment
Concerns about potential cuts to NIH funding and ongoing policy uncertainties may impact the funding landscape for biopharma innovation.
Vertex CF Royalty Dispute
Dispute with Vertex regarding the royalty status of deuterated Kalydeco remains unresolved, with no update on arbitration.
Company Guidance
During Royalty Pharma's first-quarter earnings call for 2025, several key financial metrics and strategic updates were highlighted. Royalty Receipts saw a 12% increase, contributing to a 17% rise in Portfolio Receipts, driven by a strong performance across their diversified portfolio. In terms of capital allocation, the company repurchased $723 million worth of shares, part of a larger $2 billion buyback plan for the year, and deployed over $100 million on royalty transactions. Royalty Pharma also raised its full-year guidance for Portfolio Receipts to a range between $2.975 billion and $3.125 billion, anticipating growth of 6% to 12%. The company reported a strong portfolio cash flow with an adjusted EBITDA margin of about 73%. Additionally, they highlighted several promising developments in their portfolio, including a Phase 3 R&D collaboration with Biogen and positive clinical outcomes for ecopipam in Tourette's syndrome.

Royalty Pharma Financial Statement Overview

Summary
Royalty Pharma demonstrates strong operational efficiency with impressive gross margins and robust cash flow generation. However, challenges in net income growth and profitability impact the overall financial health. Despite moderate leverage and strong equity levels, the company should focus on enhancing profitability to improve financial performance.
Income Statement
75
Positive
The income statement shows stable revenue with a slight decline over the TTM period compared to previous years. Gross profit margins remain strong, over 99%, indicating efficient cost management. However, the net profit margin has decreased due to higher expenses relative to revenue. The EBIT and EBITDA margins show strong operational efficiency, though the decline in net income suggests some profitability challenges.
Balance Sheet
70
Positive
The balance sheet indicates a moderate debt-to-equity ratio, suggesting manageable leverage levels. The equity ratio is stable, supporting financial stability. However, the return on equity (ROE) fluctuates due to varying net income, highlighting potential profitability issues. Overall, the company maintains a solid asset base with appropriate equity levels.
Cash Flow
78
Positive
Cash flows are robust, with strong operating cash flow relative to net income, indicating efficient cash generation from operations. The free cash flow remains positive, supporting financial flexibility. However, the free cash flow growth rate has slowed, suggesting a need for future improvements in cash flow generation to sustain growth.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.26B2.26B2.35B2.24B2.29B2.12B
Gross Profit2.26B2.26B1.79B2.23B2.27B2.03B
EBITDA2.33B1.29B1.89B928.56M1.45B1.68B
Net Income1.09B859.00M1.13B42.83M478.75M495.20M
Balance Sheet
Total Assets17.61B18.22B16.38B16.81B17.52B21.10B
Cash, Cash Equivalents and Short-Term Investments1.82B987.23M495.31M2.43B2.80B1.99B
Total Debt7.62B7.61B6.14B7.12B7.10B5.82B
Total Liabilities7.82B7.88B6.30B7.29B7.27B6.12B
Stockholders Equity6.69B6.95B6.53B5.63B5.78B9.90B
Cash Flow
Free Cash Flow2.70B2.77B2.99B2.14B2.02B2.03B
Operating Cash Flow2.70B2.77B2.99B2.14B2.02B2.03B
Investing Cash Flow-2.09B-2.68B-2.07B-1.03B-1.87B-2.76B
Financing Cash Flow-368.16M361.14M-2.15B-944.86M385.11M1.49B

Royalty Pharma Technical Analysis

Technical Analysis Sentiment
Positive
Last Price36.37
Price Trends
50DMA
33.65
Positive
100DMA
32.99
Positive
200DMA
30.03
Positive
Market Momentum
MACD
0.78
Negative
RSI
66.54
Neutral
STOCH
88.60
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPRX, the sentiment is Positive. The current price of 36.37 is above the 20-day moving average (MA) of 35.06, above the 50-day MA of 33.65, and above the 200-day MA of 30.03, indicating a bullish trend. The MACD of 0.78 indicates Negative momentum. The RSI at 66.54 is Neutral, neither overbought nor oversold. The STOCH value of 88.60 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RPRX.

Royalty Pharma Risk Analysis

Royalty Pharma disclosed 65 risk factors in its most recent earnings report. Royalty Pharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Royalty Pharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
84
Outperform
$12.59B20.9430.22%24.49%244.87%
78
Outperform
$20.45B14.8316.57%2.42%1.15%37.75%
78
Outperform
$12.61B11.4022.69%25.11%46.46%
74
Outperform
$13.25B211.790.47%17.13%-88.78%
58
Neutral
$26.44B-3.87%0.58%-764.64%
56
Neutral
$11.79B-29.34%-38.25%44.29%
52
Neutral
$7.50B0.31-61.87%2.27%17.10%1.59%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RPRX
Royalty Pharma
36.37
11.40
45.65%
EXEL
Exelixis
46.15
24.06
108.92%
INCY
Incyte
68.45
10.28
17.67%
GMAB
Genmab
20.30
-5.18
-20.33%
MRNA
Moderna
30.49
-85.96
-73.82%
BNTX
BioNTech SE
110.00
29.51
36.66%

Royalty Pharma Corporate Events

Private Placements and FinancingM&A TransactionsBusiness Operations and Strategy
Royalty Pharma Completes Major Acquisition and Restructuring
Neutral
May 19, 2025

Royalty Pharma has recently undergone significant restructuring and financial transactions. On May 16, 2024, RPH acquired all equity interests of RP LLC, involving a cash payment of $200 million and the issuance of 24,530,266 non-voting Class E ordinary shares. The transaction also included the assumption of a $380 million term loan facility. Additionally, the company amended its articles of association to provide new rights and streamline shareholder processes. These changes are expected to impact the company’s financial structure and governance, potentially influencing its market position and stakeholder relationships.

The most recent analyst rating on (RPRX) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Royalty Pharma stock, see the RPRX Stock Forecast page.

Shareholder MeetingsBusiness Operations and Strategy
Royalty Pharma’s Annual General Meeting Highlights
Neutral
May 12, 2025

On May 12, 2025, Royalty Pharma held its Annual General Meeting where shareholders voted on 15 proposals, including the approval of the Membership Interest Purchase Agreement and the 2025 Equity Incentive Plan. The meeting demonstrated strong shareholder engagement with 85.96% of voting power represented, and the results of the votes will impact the company’s strategic decisions and governance, including the election of nine directors and the ratification of Ernst & Young LLP as the independent auditor.

The most recent analyst rating on (RPRX) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Royalty Pharma stock, see the RPRX Stock Forecast page.

Executive/Board Changes
Royalty Pharma Appoints Dr. Vlad Coric to Board
Positive
Apr 10, 2025

On April 8, 2025, Royalty Pharma announced the appointment of Dr. Vlad Coric to its Board of Directors, effective immediately. Dr. Coric, who has extensive experience in the biopharmaceutical industry, is expected to bring significant expertise to Royalty Pharma, particularly in the royalty funding space, enhancing the company’s position as a leading partner in life sciences innovation.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 24, 2025